Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
← catalyst calendarNCT07400965 · readout ≤ 42 d
Sponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
250estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-05 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Demodex Blepharitis
Interventions
- Drug: GLK-321 low dose BID
- Drug: GLK-321 mid dose BID
- Drug: GLK-321 high dose BID
- Drug: GLK-321 high dose QD
- Drug: Placebo BID
Primary outcome
what the primary-completion date above is the date OFPercentage of study eyes with elimination of collarettes
measured 6 weeks
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed